openPR Logo
Press release

Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Pancreatic Cancer

10-19-2020 06:34 AM CET | Health & Medicine

Press release from: The Insight Partners

Pancreatic Cancer Therapy Market to 2025

Pancreatic Cancer Therapy Market to 2025

Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US.

Download sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPMD00002009/?openpr-10144

The pancreatic cancer therapy market is expected to reach US$ 4056.4 million by 2025 from US$ 2011.2 million in 2017; it is estimated to grow at a CAGR of 8.1% from 2018 to 2025.

Company Profiles

Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Amgen Inc
Novartis AG
Celgene Corporation
Merck & Co., Inc
Pharmacyte Biotech Inc
Clovis Oncology
Teva Pharmaceutical Industries Ltd
Pfizer Inc

Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.

For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.

Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.

Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.

Purchase Full Copy @ https://www.theinsightpartners.com/buy/TIPMD00002009/?openpr-10144

An outline of the regional analysis:
• Geographically, the report segments the Pancreatic Cancer Therapy market into North America, Europe, Asia-Pacific, Southeast Asia, Middle East and Africa, South America.
• Contribution of each region to the overall market share, along with their growth rate forecast are mentioned in the report.
• Total sales and revenue generated by each regional market are illustrated.
• Comprehensive assessment of all opportunities and risks in the Pancreatic Cancer Therapy market.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Pancreatic Cancer here

News-ID: 2163088 • Views: 408

More Releases from The Insight Partners

Latent TB Detection Market: Government Initiatives to Promote Tuberculosis Detec …
The growth of the market is attributed to the increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection. However, multidrug resistant tuberculosis (MDR-TB) is likely to hamper the growth of the Latent TB Detection market to a certain extent. The latent TB detection market is expected to reach US$ 1,684.86 million in 2027 from US$ 1,131.82 million in 2019. The market is estimated to grow with a CAGR of
Periodontal Therapeutics Market by latest COVID-19 Impact and Global Analysis to …
Periodontal therapeutics are products used in treatment of periodontal disease. Periodontitis is chronic bacterial infection caused due to microbial plaque often known as gum disease, which is colonized on tooth surface and below the gingival margin. Periodontal disease are caused due to hormonal changes, smoking, poor oral health hygiene and some hereditary factors. The periodontal disease involves progressive loss of alveolar bone and majorly observed in adults. The global periodontal therapeutics
Airport Biometrics Market by latest COVID-19 Impact and Global Analysis to 2028 …
The Insight Partners delivers well-researched industry-wide information on the Airport Biometrics market. It provides information on the market’s essential aspects such as top participants, factors driving Airport Biometrics market growth, precise estimation of the Airport Biometrics market size, upcoming trends, changes in consumer behavioral pattern, market’s competitive landscape, key market vendors, and other market features to gain an in-depth analysis of the market. Additionally, the report is a compilation of
Pharmaceutical Surfactants Market Report (COVID-19 Analysis) by Worldwide Market …
Surfactants are organic chemicals that are generally used in pharmaceuticals for the recovery of intracellular products and gene delivery. They can be utilized as an antimicrobial agent as they stop the nourishment of various pathogenic microbes such as bacteria, fungi, and viruses, etc., and make the pharmaceutical preparations free of microbes that are harmful. They can be categorized as anionic surfactants, non-ionic surfactants, and many more. The non-ionic surfactants are

All 5 Releases


More Releases for Pancreatic

Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Pancreatic Cancer Pipeline Drugs Review H1 2017
Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,
Research Announces: Global Pancreatic Cancer Market
MarketResearchReports.Biz is providing you Retail Market Research report of "Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017". Latest Report, Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Pancreatic Cancer Report is to understand the market and pipeline status of the drugs